Menu Search
Equities

Telix Pharmaceuticals Ltd

T3X:BER

Telix Pharmaceuticals Ltd

Actions
  • Price (EUR)9.34
  • Today's Change-0.036 / -0.38%
  • Shares traded142.00
  • 1 Year change+43.99%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024 17:34 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).

  • Revenue in AUD (TTM)502.55m
  • Net income in AUD5.21m
  • Incorporated2017
  • Employees234.00
  • Location
    Telix Pharmaceuticals LtdSuite 401 55 Flemington RoadNorth MelbourneMELBOURNE 3051AustraliaAUS
  • Websitehttps://telixpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TLX:ASX since
announced		Transaction
value
ARTMS IncAnnounced04 Mar 202404 Mar 2024Announced28.67%82.00m
IsoTherapeutics Group LLCAnnounced27 Feb 202427 Feb 2024Announced40.05%13.00m
Lightpoint Medical LtdDeal completed21 Jun 202321 Jun 2023Deal completed32.21%35.00m
Data delayed at least 20 minutes, as of May 09 2024 07:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.